Want to join the conversation?
$GILD 2Q15 Call: Non-GAAP R&D expenses were $702MM, up 30% YoverY due to continued progression and expansion of clinical studies, particularly Phase 3 studies in liver disease and oncology areas. Non-GAAP SG&A expenses were up 34% YoverY to $761MM. Ended 2Q15 with $14.7Bil in cash and investments, and generated cash flow from operations of $5.7Bil.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?